Remove 2017 Remove Licensing Remove Regulations
article thumbnail

Ascentage Pharma Enters into an Agreement with University of Michigan to obtain an exclusive license for a MDM2 Degrader using PROTAC Technology

The Pharma Data

MDM2 is a key regulator of the tumor suppressor p53 and one of the most potent inhibitors of apoptosis discovered thus far. 2017, 16 , 101-114. Ascentage Pharma is also the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators. 2015, 58 , 1038?1052.

article thumbnail

Article FDA Thank You The FDA rejected a psychedelic sponsor’s bid for approval. Here are six industry takeaways

Agency IQ

By Amanda Conti | Aug 13, 2024 10:00 PM CDT Regulatory context: Psychedelic regulation and drug development A growing body of evidence suggests that psychedelics may provide clinical benefit for certain purposes, especially mental health conditions. At that time, FDA flagged concerns with functional unblinding and inherent expectation bias.

FDA 40
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Etrasimod

New Drug Approvals

“The Selective Sphingosine 1-Phosphate Receptor Modulator Etrasimod Regulates Lymphocyte Trafficking and Alleviates Experimental Colitis” J Pharmacol Exp Ther. Peyrin-Biroulet L, Christopher R, Behan D, Lassen C (May 2017). Retrieved 13 October 2023. ^ [link] ^ World Health Organization (2017). 369 (3): 311–317.

FDA 57
article thumbnail

AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio

The Pharma Data

Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. The lead molecule, SDI-118, was discovered by UCB before being out-licensed to Syndesi as of 2018.

article thumbnail

Analysis Life Sciences Thank You What We Expect the FDA to do in August and September 2024

Agency IQ

What We Expect the FDA to do in August and September 2024 In this ongoing feature, AgencyIQ looks at public data to determine what the FDA is likely to do in the months ahead, including key deadlines, meetings, events, planned regulations, comment periods and more. The following PDUFA dates were obtained from publicly available sources.

FDA 40
article thumbnail

MorphoSys To Present At the 39th Annual J.P. Morgan Healthcare Conference

The Pharma Data

In 2017, Tremfya (R) , developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc., for the treatment of plaque psoriasis, became the first drug based on MorphoSys’ antibody technology to receive regulatory approval. For more information, please contact: SOURCE: MorphoSys AG via EQS Newswire.

article thumbnail

Surely You Must be Kidding, PTO?!? “No, and Don’t Call Me Shirley!” – The Seemingly Slapstick (But Yet Unfunny) World of Recent Patent Term Extension Decisions (PART 2)

FDA Law Blog: Biosimilars

156, as added by the 1984 Hatch-Waxman Amendments, for certain FDA-regulated products. FDA-2017-E-5106 ), and concerns FDA’s October 19, 2016 Accelerated Approval of BLA 761038 for LARTRUVO (olaratumab). Karst — Earlier this week, we posted Part 1 of our three-part series on U.S. 8,128,929 [] for [PTE] request under 35 U.S.C. §

FDA 59